Search Results - "Borad, M. J."

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study by Uson, P. L. S., Kunze, K. L., Golafshar, M. A., Botrus, G., Riegert-Johnson, D., Boardman, L., Borad, M. J., Ahn, D., Sonbol, M. B., Kahn, A., Klint, M., Esplin, E. D., Nussbaum, R. L., Stewart, A. K., Bekaii-Saab, T., Samadder, N. J.

“…Background and Aims To determine prevalence and clinical utility of pathogenic germline variants (PGV) in gastric and esophageal cancer patients using…”
Get full text

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma by Borad, M J, Swift, R, Berenson, J R

Get full text

SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt by Iesa, M.A.M., Osman, M.E.M., Hassan, M.A., Dirar, A.I.A., Abuzeid, N., Mancuso, J.J., Pandey, R., Mohammed, A.A., Borad, M.J., Babiker, H.M., Konozy, E.H.E.

“…Coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality and new cases are on the rise globally, yet malaria-endemic areas report…”
Get full text

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials by Uson Junior, P.L.S., Dias e Silva, D., de Castro, N.M., da Silva Victor, E., Rother, E.T., Araújo, S.E.A., Borad, M.J., Moura, F.

“…Neoadjuvant chemotherapy may improve overall survival (OS) in ‘borderline’ resectable pancreatic cancer (RPC). Whether the results are the same in upfront RPC…”
Get full text

HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer by Oh, D.-Y., Park, J.-O., Charoentum, C., Stein, S., Noel, M., Chung, V., Wu, W., Alton, R., Muhsin, M., Javle, M., Abou-Alfa, G.K., Borad, M.J.

Get full text

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 by Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Veronese, M.L., Abou-Alfa, G.K.

“…Fibroblast growth factor receptor 2 (FGFR2) fusions and rearrangements are clinically actionable genomic alterations in cholangiocarcinoma (CCA). Pemigatinib…”
Get full text

Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2 by Marschke, R. F., Borad, M. J., McFarland, R. W., Alvarez, R. H., Lim, J. K., Padgett, C. S., Von Hoff, D. D., O'Brien, S. E., Northfelt, D. W.

“…Abstract only…”
Get full text

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum] by Babiker, H.M, Riaz, I.B, Husnain, M, Borad, M.J

Get full text

726PFGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA) by Almquist, D R, Javle, M, Ciombor, K K, Roth, M, Abdel-Wahab, R, Ou, F-S, Wolfe, E, Mody, K, Mahipal, A, Borad, M J, Bekaii-Saab, T, Ahn, D

“…Abstract Background iCCA is a genomically diverse disease where various genomic alterations have been identified. FGFR2 fusions are present in up to 15% of…”
Get full text

730PPhase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC) by Chakrabarti, S, Zemla, T, Ou, F-S, Fruth, B, Ahn, D, Borad, M J, Hartgers, M L, Wessling, J, Walkes, R L, Alberts, S, McWilliams, R R, Liu, M C, Mahipal, A

“…Abstract Background Advanced BTC is an aggressive neoplasm with median overall survival (OS) of less than a year with current therapy. There is no approved…”
Get full text

211TiPHALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer by Oh, D-Y, Park, J-O, Charoentum, C, Stein, S, Noel, M, Chung, V, Wu, W, Alton, R, Muhsin, M, Javle, M, Abou-Alfa, G K, Borad, M J

Get full text

LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) by Vogel, A, Sahai, V, Hollebecque, A, Vaccaro, G, Melisi, D, Al-Rajabi, R, Paulson, A S, Borad, M J, Gallinson, D, Murphy, A G, Oh, D-Y, Dotan, E, Catenacci, D V, Van Cutsem, E, Lihou, C F, Zhen, H, Féliz, L, Abou-Alfa, G K

“…Abstract Background Fibroblast growth factor receptor (FGFR) 2 alterations are implicated in CCA. Pemigatinib is a selective, potent, oral FGFR1, 2, and 3…”
Get full text

LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation by Abou-Alfa, G K, Macarulla Mercade, T, Javle, M, Kelley, R K, Lubner, S, Adeva, J, Cleary, J M, Catenacci, D V, Borad, M J, Bridgewater, J A, Harris, W P, Murphy, A G, Oh, D-Y, Whisenant, J, Wu, B, Jiang, L, Gliser, C, Pandya, S S, Valle, J W, Zhu, A X

“…Abstract Background CC is a rare cancer for which there are limited effective therapies. IDH1 mutations occur in up to ∼15% of CC, resulting in production of…”
Get full text

Treatment (Tx) guidelines for skin and mucosal events in patients with solid tumors (pts) receiving TH‐302, a tumor selective, hypoxia‐activated prodrug by Borad, M. J., Boyer, N., Curd, J. G., Sunkara, U. K., Awerkamp, K., Lacouture, M. E.

“…Abstract only…”
Get full text

CO78 Matching-Adjusted Indirect Comparison of Futibatinib Versus Chemotherapy and Pemigatinib in Cholangiocarcinoma Patients With FGFR2 Fusions/Rearrangements by Paine, A, Thom, H, Wacheck, V, He, Y, Kazerooni, R, Salimi, T, Borad, MJ, Bridgewater, J

Get full text

Phase I trial of everolimus and gemcitabine for patients with solid tumors refractory to standard therapy and for a cohort of patients with cholangiocarcinoma/gallbladder cancer by Costello, B. A., Qi, Y., Borad, M. J., Kim, G. P., Northfelt, D. W., Erlichman, C., Alberts, S. R.

“…Abstract only…”
Get full text

Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer by Borad, M. J., Reddy, S., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., Ulrich, B., Dragovich, T., Prete, S. Del, Rarick, M., Eng, C., Kroll, S., Ryan, D.

“…A hypoxic microenvironment is believed to be a characteristic of solid tumors including pancreatic adenocarcinoma (PAC) and is associated with resistance to…”
Get full text

Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study by Marcano-Bonilla, Lorena, Schleck, Cathy D, Harmsen, William S, Sadr-Azodi, Omid, Borad, Mitesh J, Patel, Tushar, Petersen, Gloria M, Therneau, Terry M, Roberts, Lewis R, Brusselaers, Nele

“…Chemoprevention for biliary tract cancers (BTC), which comprise intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder…”
Get full text

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date by Uson Junior, Pedro Luiz Serrano, Borad, Mitesh J

“…Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved for patients with IDH1 mutation and acute myeloid leukemia and previously…”
Get full text

Safety and activity of TH-302, a hypoxia-activated cytotoxic prodrug (HAP), in patients with metastatic melanoma and lung cancer by Weber, R. W., Weiss, G. J., Chiorean, E. G., Senzer, N. N., Borad, M. J., Markovic, S., Molina, J. R., Langmuir, V. K., Lee, H., Infante, J. R.

“…Abstract only…”
Get full text